FLGT Stock Analysis: Fulgent Genetics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 597m USD | 12M Return: -16.2% | US3596641098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.38M
Qual. Beats: 0
Rev. Trend: 85.7%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fulgent Genetics, Inc. (NASDAQ: FLGT) is a U.S.-based healthcare services company headquartered in El Monte, California, that provides clinical diagnostic and therapeutic development solutions to physicians and patients domestically and internationally. The company was founded in 2011 and operates in the Health Care Services sub-industry, competing in a clinical laboratory services landscape alongside larger diagnostics peers such as Quest Diagnostics and Laboratory Corporation of America.
The companys clinical diagnostic offerings span molecular diagnostic testing, genetic testing, and a broad menu of anatomic pathology laboratory tests covering gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology specialties, along with oncology testing and sequencer services for hereditary cancer, reproductive health, and other disease areas. This multi-modality testing approach is characteristic of integrated clinical laboratory business models that bundle molecular, genetic, and anatomic pathology services under one provider.
In addition to diagnostics, Fulgent pursues therapeutic development focused on cancer drug candidates built around a proprietary nanoencapsulation and targeted therapy platform intended to improve the therapeutic window and pharmacokinetic profile of new and existing oncology drugs. The company also operates the Picture Genetics platform, which integrates gene probes, data suppression and comparison algorithms, adaptive learning software, and a proprietary laboratory information management system to help customers identify health markers in personal DNA.
Fulgent serves a diverse customer base that includes insurance companies, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients directly. The company was originally named Fulgent Diagnostics, Inc. and adopted its current name in August 2016, shortly before its September 2016 IPO on NASDAQ.
- COVID test revenue declines as pandemic demand normalizes
- Core genomic testing volumes expand with hereditary cancer demand
- Cash deployment for acquisitions or share repurchases supports capital returns
| Net Income: -84.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA -4.53 > 1.0 |
| NWC/Revenue: 118.2% < 20% (prev 117.9%; Δ 0.37% < -1%) |
| CFO/TA -0.08 > 3% & CFO -83.7m > Net Income -84.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.0m) vs 12m ago -9.17% < -2% |
| Gross Margin: 35.58% > 18% (prev 40.04%; Δ -4.45% > 0.5%) |
| Asset Turnover: 28.30% > 50% (prev 25.27%; Δ 3.03% > 0%) |
| Interest Coverage Ratio: -381.7 > 6 (EBIT TTM -90.8m / Interest Expense TTM 238k) |
| A: 0.35 (Total Current Assets 454.8m - Total Current Liabilities 71.8m) / Total Assets 1.09b |
| B: 0.44 (Retained Earnings 475.6m / Total Assets 1.09b) |
| C: -0.08 (EBIT TTM -90.8m / Avg Total Assets 1.14b) |
| D: 10.74 (Book Value of Equity 1.00b / Total Liabilities 93.2m) |
| Altman-Z'' = 14.48 = AAA |
| DSRI: 0.78 (Receivables 70.5m/85.0m, Revenue 323.9m/303.2m) |
| GMI: 1.13 (GM 40.04% / 35.58%) |
| AQI: 0.87 (AQ_t 0.48 / AQ_t-1 0.55) |
| SGI: 1.07 (Revenue 323.9m / 303.2m) |
| TATA: -0.00 (NI -84.4m - CFO -83.7m) / TA 1.09b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of November 05, 2026, the stock is trading at USD 19.37 with a total of 284,379 shares traded. Over the past week, the price has changed by -6.43%, over one month by -13.72%, over three months by +9.99% and over the past year by -16.18%.
Current recommended Stop Loss: 17.30 (which is 10.7% or 2.4 ATR below the current price).
Fulgent Genetics has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold FLGT.
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19 | -1.9% |
P/E Forward = 7.7042
P/S = 1.8415
P/B = 0.5909
P/EG = 1.32
Revenue TTM = 323.9m USD
EBIT TTM = -90.8m USD
EBITDA TTM = -65.0m USD
Long Term Debt = 1.48m USD (from longTermDebt, last quarter)
Short Term Debt = 2.34m USD (from shortTermDebt, last quarter)
Debt = 16.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.46m
Net Debt = -240.1m USD (calculated: Debt 16.9m - CCE 257.0m)
Enterprise Value = 356.4m USD (596.5m + Debt 16.9m - CCE 257.0m)
Interest Coverage Ratio = -381.7 (Ebit TTM -90.8m / Interest Expense TTM 238k)
EV/FCF = -3.43x (Enterprise Value 356.4m / FCF TTM -103.8m)
FCF Yield = -29.12% (FCF TTM -103.8m / Enterprise Value 356.4m)
FCF Margin = -32.04% (FCF TTM -103.8m / Revenue TTM 323.9m)
Net Margin = -26.05% (Net Income TTM -84.4m / Revenue TTM 323.9m)
Gross Margin = 35.58% ((Revenue TTM 323.9m - Cost of Revenue TTM 208.7m) / Revenue TTM)
Gross Margin QoQ = 30.07% (prev 30.21%)
Tobins Q-Ratio = 0.33 (Enterprise Value 356.4m / Total Assets 1.09b)
Interest Expense / Debt = 1.41% (Interest Expense 238k / Debt 16.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -71.8m (EBIT -90.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.34 (Total Current Assets 454.8m / Total Current Liabilities 71.8m)
Debt / Equity = 0.02 (Debt 16.9m / totalStockholderEquity, last quarter 1.00b)
Debt / EBITDA = 3.69 (negative EBITDA) (Net Debt -240.1m / EBITDA -65.0m)
Debt / FCF = 2.31 (negative FCF - burning cash) (Net Debt -240.1m / FCF TTM -103.8m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.37% (Net Income -84.4m / Total Assets 1.09b)
RoE = -7.87% (Net Income TTM -84.4m / Total Stockholder Equity 1.07b)
RoCE = -8.46% (EBIT -90.8m / Capital Employed (Equity 1.07b + L.T.Debt 1.48m))
RoIC = -7.15% (negative operating profit) (NOPAT -71.8m / Invested Capital 1.00b)
WACC = 5.96% (E(596.5m)/V(613.4m) * Re(6.10%) + D(16.9m)/V(613.4m) * Rd(1.41%) * (1-Tc(0.21)))
Discount Rate = 6.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.19 | Cagr: -2.68%
[DCF] Fair Price = unknown (Cash Flow -103.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.57 | # QB: 0
Revenue Correlation: 85.70 | Revenue CAGR: 5.44% | SUE: -2.90 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.65 | Chg30d=-80.56% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-2.27 | Chg30d=-46.45% | Revisions=-25% | GrowthEPS=-640.5% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=-1.38 | Chg30d=-20.00% | Revisions=-25% | GrowthEPS=+39.2% | GrowthRev=+15.4%